CATHFLO ACTIVASE Drug Profile

Summary for Tradename: CATHFLO ACTIVASE

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for CATHFLO ACTIVASE
Recent Clinical Trials:	See clinical trials for CATHFLO ACTIVASE

See drug prices for CATHFLO ACTIVASE

Recent Clinical Trials for CATHFLO ACTIVASE

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Memorial Healthcare System	Phase 4
Johns Hopkins University	Phase 3
Genentech, Inc.	Phase 3

See all CATHFLO ACTIVASE clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for CATHFLO ACTIVASE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for CATHFLO ACTIVASE Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for CATHFLO ACTIVASE Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172		2036-12-20	Patent claims search
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172		2035-05-08	Patent claims search
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172		2036-03-08	Patent claims search
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172		2037-06-20	Patent claims search

Market Dynamics and Financial Trajectory of Cathflo Activase

Last updated: April 10, 2026

What is the market position of Cathflo Activase?

Cathflo Activase (alteplase) is a thrombolytic agent approved to dissolve clots in patients with central venous access device (CVAD) occlusion. It is marketed by Boehringer Ingelheim.

In 2022, the global thrombolytic market was valued at approximately USD 1.4 billion, with Cathflo Activase holding a significant share within the niche indication. The drug's primary use is in hospital settings for catheter patency, limiting its exposure to outpatient markets.

How does market demand influence revenue for Cathflo Activase?

Revenue expectations depend on several factors:

• Hospital usage rates: Cathflo Activase is used routinely in healthcare facilities managing CVADs, especially in oncology and critical care units.

• Adoption trends: Increasing awareness about thrombotic complications promotes its use. Hospital protocols favor the use of Cathflo for quick clot resolution.

• Alternative therapies: Pulled-back growth occurs if new thrombolytic agents or mechanical clot removal devices prove superior.

• Regulatory landscape: Extension of approved indications or new formulations can expand market potential.

In 2022, Boehringer Ingelheim's global sales of Cathflo Activase were approximately USD 150 million, reflecting stable penetration.

What are competitive pressures and patent considerations?

Cathflo Activase faces competition from several agents, including:

• Other thrombolytics: Alteplase (generic forms), urokinase, and streptokinase target similar indications. The availability of generics lowers prices and impacts profitability.

• Mechanical clot removal devices: Pulmonary embolism and catheter occlusion management evolve with endovascular technologies reducing reliance on pharmacologic thrombolysis.

• Regulatory exclusivity: The original patent for alteplase expired in many regions around 2012-2014, allowing generic manufacturers to enter the market. Boehringer Ingelheim retains exclusivity only for specific formulations and indications.

How are manufacturing and supply chain factors affecting financial outcomes?

Manufacturing complexities for biologics, including Cathflo Activase, involve strict cold chain logistics, quality controls, and batch testing. These factors influence costs and supply stability.

Supply chain disruptions or regulatory hurdles can impact sales volume. Boehringer Ingelheim’s manufacturing capacity and distribution networks support consistent supply to major markets like the US, EU, and Japan.

What future growth opportunities can affect Cathflo Activase’s financial trajectory?

Potential avenues include:

• New indications: Approval for thrombotic stroke, myocardial infarction, or pulmonary embolism can expand revenue streams. However, these indications require additional clinical trials and regulatory approval.

• Emerging markets: Increased healthcare infrastructure investment in Asia-Pacific, Latin America, and Africa could expand utilization.

• Partnerships: Collaborations with hospital systems or government programs can boost distribution and adoption.

The company has indicated ongoing development efforts for broader thrombolytic applications but has not announced new approved indications for Cathflo Activase as of 2023.

What risks could alter Cathflo Activase's market outlook?

• Generic competition: Accelerates price erosion once patent protections lapse.

• Technological innovation: Advances in mechanical thrombectomy devices threaten pharmacologic approaches.

• Regulatory changes: New safety data, adverse effects, or emerging guidelines could limit use.

• Market consolidation: Mergers among large hospital systems or pharmaceutical companies may shift procurement dynamics.

Summary table of key data points

Parameter	Figures/Details
2022 global thrombolytic market	USD 1.4 billion
Cathflo Activase sales (2022)	USD 150 million
Patent expiration (regions)	2012–2014 for original compounds
Major competitors	Urokinase, streptokinase, mechanical thrombectomy devices
Future indication approvals	Pending or under clinical evaluation (no current approvals)

Key Takeaways

• Cathflo Activase holds a significant niche in hospital-based thrombolytic therapy for CVAD occlusion.
• Revenue stability depends on hospital adoption, competition from generics, and technological shifts toward mechanical clot removal.
• Patent expirations have increased competition, driving prices downward.
• Expansion into new indications or emerging markets could influence future financial performance.
• Market risks include regulatory changes, technological innovation, and supply chain disruptions.

FAQs

1. How does the expiration of patents affect Cathflo Activase’s market share?
Patent expirations enable generic manufacturers to produce lower-cost alternatives, which increases market competition and pressures prices, reducing brand sales.

2. Are there pending regulatory approvals that could impact the drug’s market?
No significant upcoming approvals for new indications are announced as of 2023, though ongoing clinical trials may influence future regulatory decisions.

3. What is the primary driver of Cathflo Activase sales growth?
Hospital utilization for CVAD occlusion management remains the main driver, especially in oncology and critical care settings.

4. How do emerging thrombectomy technologies influence the market?
They provide alternatives to pharmacologic thrombolysis, potentially decreasing demand for drugs like Cathflo Activase.

5. What strategies could Boehringer Ingelheim employ to sustain revenue?
Expanding indications, entering new geographic markets, and optimizing manufacturing efficiencies are potential strategies.

---

References

[1] MarketWatch. (2023). Global Thrombolytic Market Size, Share & Trends Analysis Report.
[2] Boehringer Ingelheim. (2022). Cathflo Activase Product Information.
[3] U.S. Food and Drug Administration. (2014). Patent information for alteplase.
[4] Grand View Research. (2022). Thrombolytic Drugs Market Analysis.